Cargando…
Up-regulation of SR-BI promotes progression and serves as a prognostic biomarker in clear cell renal cell carcinoma
BACKGROUND: Scavenger receptor class B type I (SR-BI) has been reported to be involved in carcinogenesis of several human cancers. However, it is currently unknown whether SR-BI plays a role in clear cell renal cell carcinoma (ccRCC). Here, we aimed to evaluate a tumor promotive mechanism for SR-BI...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5778766/ https://www.ncbi.nlm.nih.gov/pubmed/29357836 http://dx.doi.org/10.1186/s12885-017-3761-z |
_version_ | 1783294422086057984 |
---|---|
author | Xu, Guang-hua Lou, Ning Shi, Hang-chuan Xu, Yu-chen Ruan, Hai-long Xiao, Wen Liu, Lei Li, Xiang Xiao, Hai-bing Qiu, Bin Bao, Lin Yuan, Chang-fei Zhou, Ya-li Hu, Wen-jun Chen, Ke Yang, Hong-mei Zhang, Xiao-ping |
author_facet | Xu, Guang-hua Lou, Ning Shi, Hang-chuan Xu, Yu-chen Ruan, Hai-long Xiao, Wen Liu, Lei Li, Xiang Xiao, Hai-bing Qiu, Bin Bao, Lin Yuan, Chang-fei Zhou, Ya-li Hu, Wen-jun Chen, Ke Yang, Hong-mei Zhang, Xiao-ping |
author_sort | Xu, Guang-hua |
collection | PubMed |
description | BACKGROUND: Scavenger receptor class B type I (SR-BI) has been reported to be involved in carcinogenesis of several human cancers. However, it is currently unknown whether SR-BI plays a role in clear cell renal cell carcinoma (ccRCC). Here, we aimed to evaluate a tumor promotive mechanism for SR-BI in ccRCC. METHODS: The expression of SR-BI was evaluated by real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR), Western blot and immunohistochemistry (IHC) in ccRCC tissues and cell lines. Lipid droplets in ccRCC tissues and normal kidney tissues were examined by Oil Red O (ORO) and hematoxylin-eosin (HE) staining. The correlation between SR-BI mRNA levels and clinicopathological features was analyzed by Pearson’s chi-square test or Fisher’s exact test. Kaplan-Meier analysis and Cox model were used to evaluate the difference in progression-free survival (PFS) associated with expression of SR-BI. Inhibition of SR-BI was conducted by using small interfering RNA (siRNA). In vitro assays were performed to assess the impact of SR-BI knockdown on cell biological behaviors. High density lipoprotein (HDL)-cholesterol content in ccRCC cells and extracellular media was also measured after transfection with siRNA. RESULTS: The expression of SR-BI was markedly up-regulated in ccRCC tissues and tumor cell lines. ORO and HE staining revealed huge amounts of lipid droplets accumulation in ccRCC. Clinical analysis showed that over-expression of SR-BI was positively associated with tumor size, grade, distant metastasis and inversely correlated with PFS. Furthermore, SR-BI was proved to be an independent prognostic marker in ccRCC patients. The inhibition of SR-BI attenuated the tumorous behaviors of ccRCC cells, expression of metastasis and AKT pathway related proteins. The content of HDL-cholesterol was reduced in cells while increased in extracellular media after transfection with si-SR-BI. CONCLUSIONS: Our results demonstrate that SR-BI functions as an oncogene and promotes progression of ccRCC. SR-BI may serve as a potential prognostic biomarker and therapeutic target for ccRCC. |
format | Online Article Text |
id | pubmed-5778766 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-57787662018-01-31 Up-regulation of SR-BI promotes progression and serves as a prognostic biomarker in clear cell renal cell carcinoma Xu, Guang-hua Lou, Ning Shi, Hang-chuan Xu, Yu-chen Ruan, Hai-long Xiao, Wen Liu, Lei Li, Xiang Xiao, Hai-bing Qiu, Bin Bao, Lin Yuan, Chang-fei Zhou, Ya-li Hu, Wen-jun Chen, Ke Yang, Hong-mei Zhang, Xiao-ping BMC Cancer Research Article BACKGROUND: Scavenger receptor class B type I (SR-BI) has been reported to be involved in carcinogenesis of several human cancers. However, it is currently unknown whether SR-BI plays a role in clear cell renal cell carcinoma (ccRCC). Here, we aimed to evaluate a tumor promotive mechanism for SR-BI in ccRCC. METHODS: The expression of SR-BI was evaluated by real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR), Western blot and immunohistochemistry (IHC) in ccRCC tissues and cell lines. Lipid droplets in ccRCC tissues and normal kidney tissues were examined by Oil Red O (ORO) and hematoxylin-eosin (HE) staining. The correlation between SR-BI mRNA levels and clinicopathological features was analyzed by Pearson’s chi-square test or Fisher’s exact test. Kaplan-Meier analysis and Cox model were used to evaluate the difference in progression-free survival (PFS) associated with expression of SR-BI. Inhibition of SR-BI was conducted by using small interfering RNA (siRNA). In vitro assays were performed to assess the impact of SR-BI knockdown on cell biological behaviors. High density lipoprotein (HDL)-cholesterol content in ccRCC cells and extracellular media was also measured after transfection with siRNA. RESULTS: The expression of SR-BI was markedly up-regulated in ccRCC tissues and tumor cell lines. ORO and HE staining revealed huge amounts of lipid droplets accumulation in ccRCC. Clinical analysis showed that over-expression of SR-BI was positively associated with tumor size, grade, distant metastasis and inversely correlated with PFS. Furthermore, SR-BI was proved to be an independent prognostic marker in ccRCC patients. The inhibition of SR-BI attenuated the tumorous behaviors of ccRCC cells, expression of metastasis and AKT pathway related proteins. The content of HDL-cholesterol was reduced in cells while increased in extracellular media after transfection with si-SR-BI. CONCLUSIONS: Our results demonstrate that SR-BI functions as an oncogene and promotes progression of ccRCC. SR-BI may serve as a potential prognostic biomarker and therapeutic target for ccRCC. BioMed Central 2018-01-22 /pmc/articles/PMC5778766/ /pubmed/29357836 http://dx.doi.org/10.1186/s12885-017-3761-z Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Xu, Guang-hua Lou, Ning Shi, Hang-chuan Xu, Yu-chen Ruan, Hai-long Xiao, Wen Liu, Lei Li, Xiang Xiao, Hai-bing Qiu, Bin Bao, Lin Yuan, Chang-fei Zhou, Ya-li Hu, Wen-jun Chen, Ke Yang, Hong-mei Zhang, Xiao-ping Up-regulation of SR-BI promotes progression and serves as a prognostic biomarker in clear cell renal cell carcinoma |
title | Up-regulation of SR-BI promotes progression and serves as a prognostic biomarker in clear cell renal cell carcinoma |
title_full | Up-regulation of SR-BI promotes progression and serves as a prognostic biomarker in clear cell renal cell carcinoma |
title_fullStr | Up-regulation of SR-BI promotes progression and serves as a prognostic biomarker in clear cell renal cell carcinoma |
title_full_unstemmed | Up-regulation of SR-BI promotes progression and serves as a prognostic biomarker in clear cell renal cell carcinoma |
title_short | Up-regulation of SR-BI promotes progression and serves as a prognostic biomarker in clear cell renal cell carcinoma |
title_sort | up-regulation of sr-bi promotes progression and serves as a prognostic biomarker in clear cell renal cell carcinoma |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5778766/ https://www.ncbi.nlm.nih.gov/pubmed/29357836 http://dx.doi.org/10.1186/s12885-017-3761-z |
work_keys_str_mv | AT xuguanghua upregulationofsrbipromotesprogressionandservesasaprognosticbiomarkerinclearcellrenalcellcarcinoma AT louning upregulationofsrbipromotesprogressionandservesasaprognosticbiomarkerinclearcellrenalcellcarcinoma AT shihangchuan upregulationofsrbipromotesprogressionandservesasaprognosticbiomarkerinclearcellrenalcellcarcinoma AT xuyuchen upregulationofsrbipromotesprogressionandservesasaprognosticbiomarkerinclearcellrenalcellcarcinoma AT ruanhailong upregulationofsrbipromotesprogressionandservesasaprognosticbiomarkerinclearcellrenalcellcarcinoma AT xiaowen upregulationofsrbipromotesprogressionandservesasaprognosticbiomarkerinclearcellrenalcellcarcinoma AT liulei upregulationofsrbipromotesprogressionandservesasaprognosticbiomarkerinclearcellrenalcellcarcinoma AT lixiang upregulationofsrbipromotesprogressionandservesasaprognosticbiomarkerinclearcellrenalcellcarcinoma AT xiaohaibing upregulationofsrbipromotesprogressionandservesasaprognosticbiomarkerinclearcellrenalcellcarcinoma AT qiubin upregulationofsrbipromotesprogressionandservesasaprognosticbiomarkerinclearcellrenalcellcarcinoma AT baolin upregulationofsrbipromotesprogressionandservesasaprognosticbiomarkerinclearcellrenalcellcarcinoma AT yuanchangfei upregulationofsrbipromotesprogressionandservesasaprognosticbiomarkerinclearcellrenalcellcarcinoma AT zhouyali upregulationofsrbipromotesprogressionandservesasaprognosticbiomarkerinclearcellrenalcellcarcinoma AT huwenjun upregulationofsrbipromotesprogressionandservesasaprognosticbiomarkerinclearcellrenalcellcarcinoma AT chenke upregulationofsrbipromotesprogressionandservesasaprognosticbiomarkerinclearcellrenalcellcarcinoma AT yanghongmei upregulationofsrbipromotesprogressionandservesasaprognosticbiomarkerinclearcellrenalcellcarcinoma AT zhangxiaoping upregulationofsrbipromotesprogressionandservesasaprognosticbiomarkerinclearcellrenalcellcarcinoma |